csDMARD联合TNF抑制剂对中轴型脊柱关节炎药物留存与临床缓解的影响
本研究基于13个欧洲登记数据库的24171例中轴型脊柱关节炎患者,比较首次TNF抑制剂单药治疗与联合csDMARD治疗的基线特征、1年药物留存率和缓解率,并探索外周关节炎的影响。联合治疗组基线外周关节炎更多、CRP更高;1年TNF抑制剂留存率单药组为79%、联合组为82%,缓解率分别为20%和22%,校正OR为1.16。作者认为两组1年治疗结局相似,但国家间异质性较大,限制了对可能从联合治疗获益的特定亚组(如外周关节炎)的识别。
要点
- 24171例中轴型脊柱关节炎患者中32%接受csDMARD联合治疗,各国比例13.5%至71.2%。
- 1年TNF抑制剂留存率:单药组79% vs 联合组82%(P<0.001)。
- 1年缓解率:单药组20% vs 联合组22%(P<0.001),校正OR为1.16(1.07,1.25)。
核心结论
- 作者认为这项大型欧洲研究显示,中轴型脊柱关节炎患者中TNF抑制剂单药治疗与csDMARD联合治疗的1年治疗结局相似,但国家间存在相当大的异质性,限制了对可能从联合治疗获益的特定亚组(如外周关节炎)的识别。
研究设计与样本
- 数据来自13个欧洲登记数据库,纳入24171例开始首次TNF抑制剂治疗的中轴型脊柱关节炎患者,比较单药治疗与csDMARD联合治疗。
- 采用logistic回归计算达到缓解的校正OR,采用随机效应Meta分析评估登记数据库间异质性,异质性不显著时合并结果。
- 外周关节炎定义为基线(即TNF抑制剂开始时)≥1个肿胀关节。
主要发现
- 24171例患者中32%接受csDMARD联合治疗,各国比例范围为13.5%至71.2%。
- 联合治疗组基线外周关节炎更多、CRP高于单药治疗组。
- 1年TNF抑制剂留存率(95%CI):单药组79%(78,79%),联合组82%(81,83%),P<0.001。
- 缓解率:单药组20%,联合组22%,P<0.001;校正OR为1.16(1.07,1.25)。
- 伴或不伴外周关节炎的患者12个月缓解率相似。
关键数值与推荐
- 缓解定义为ASDAS-CRP<1.3和/或BASDAI<2(原文如此)。
- 1年TNF抑制剂留存率(95%CI):单药组79%(78,79%),联合组82%(81,83%),P<0.001。
- 缓解率:单药组20%,联合组22%,P<0.001;校正OR为1.16(1.07,1.25)。
- 外周关节炎定义为基线(TNF抑制剂开始时)≥1个肿胀关节。
临床怎么用
- 原文未据此给出推荐。
局限性
- 国家间存在相当大的异质性,限制了对可能从联合治疗获益的特定亚组(如外周关节炎)的识别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Many axial spondylarthritis (axSpA) patients receive a conventional synthetic DMARD (csDMARD) in combination with a TNF inhibitor (TNFi). However, the value of this co-therapy remains unclear. The objectives were to describe the characteristics of axSpA patients initiating a first TNFi as monotherapy compared with co-therapy with csDMARD, to compare one-year TNFi retention and remission rates, and to explore the impact of peripheral arthritis. METHODS: Data was collected from 13 European registries. One-year outcomes included TNFi retention and hazard ratios (HR) for discontinuation with 95% CIs. Logistic regression was performed with adjusted odds ratios (OR) of achieving remission (Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP < 1.3 and/or BASDAI < 2) and stratified by treatment. Inter-registry heterogeneity was assessed using random-effect meta-analyses, combined results were presented when heterogeneity was not significant. Peripheral arthritis was defined as ≥1 swollen joint at baseline (=TNFi start). RESULTS: Amongst 24 171 axSpA patients, 32% received csDMARD co-therapy (range across countries: 13.5% to 71.2%). The co-therapy group had more baseline peripheral arthritis and higher CRP than the monotherapy group. One-year TNFi-retention rates (95% CI): 79% (78, 79%) for TNFi monotherapy vs 82% (81, 83%) with co-therapy (P < 0.001). Remission was obtained in 20% on monotherapy and 22% on co-therapy (P < 0.001); adjusted OR of 1.16 (1.07, 1.25). Remission rates at 12 months were similar in patients with/without peripheral arthritis. CONCLUSION: This large European study of axial SpA patients showed similar one-year treatment outcomes for TNFi monotherapy and csDMARD co-therapy, although considerable heterogeneity across countries limited the identification of certain subgroups (e.g. peripheral arthritis) that may benefit from co-therapy.
引用
- Nissen M, Delcoigne B, Di Giuseppe D, et al. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis. Rheumatology (Oxford). 2022. PMID: 35323903. doi:10.1093/rheumatology/keac174
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。